Clinical Trial Update: A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy trial of Dimebon (latrepirdine) in moderate-to-severe Alzheimer's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Dimebon (latrepirdine)

Snippet

Sponsor: Medivation, Inc. | Conditions: Moderate to Severe Alzheimer | Phase 3 | Status: TERMINATED